

News Release

Newport Beach, CA – September 20, 2019



Jack A. Syage, CEO, Elected Fellow of the American Physical Society

Prestigious recognition for outstanding contributions to physics

Today the American Physical Society (APS) announced that Jack A. Syage PhD, and CEO of ImmunogenX, was inducted as an APS Fellow due to his outstanding contributions to physics with a special emphasis on the diversity of his original research to other fields including commercial applications benefiting humankind. The citation for this honor is:

“For the development of time-resolved methods for studying chemical dynamics in molecular clusters, state-specific, angle-velocity resolved direct imaging, and for pioneering the commercial development of atmospheric pressure photoionization for mainstream mass spectrometric chemical analysis.”

The bestowing of this honor by Dr. Syage’s peers represents a truly selective achievement limited each year to no more than one half of one percent of the membership.

Dr. Syage comments, “I am sincerely humbled by the recognition of my peers for the importance and timeliness of this earlier career work of mine and for the significant impact it has played more recently to directly benefit society. I pursued chemical physics research for the sheer pleasure and intellectual challenge. I am elated to have applied these accomplishments and lessons learned to equally challenging scientific problems in the commercial sector motivated by the desire to benefit society as a whole.”

The APS Fellows will be presented at an exclusive Reception at the California Institute of Technology, Pasadena on Thursday, October 17, 2019. The APS Fellows will also be announced at the General Division of Chemical Physics Meeting in Denver on March 2-6, 2020 as part of the larger 2020 APS Annual Spring Meeting.

About ImmunogenX

ImmunogenX® (a subsidiary of Immunogenics LLC) is a clinical-stage biotherapeutics company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing latiglutenase for celiac disease therapy. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCel™) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. For food safety, ImmunogenX is pioneering advanced mass spectrometry methods to identify and measure physiologically relevant gluten peptide sequences found in wheat, barley, and rye.

www.immunogenx.com

For further information please contact

Matthew Dickason, COO
(949) 679-0900
mdickason@immunogenx.com